Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dapagliflozin on glucose flux, lipolysis and ketogenesis after insulin withdrawal
2015-002094-38Phase 4Unknown
- Sponsor
- University of Leicester
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in diabetes mellitus type 1 (T1D) and pancreatogenic diabetes mellitus (T3cDM) comparing Dapagliflozin (Forxiga) arm with Placebo arm (2 arms). Primary endpoint: Plasma glucose concentration at 600 minutes following insulin cessation or at glycaemic rescue. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)pancreatogenic diabetes mellitus (T3cDM)
Beyond the preview
Go deeper on 2015-002094-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002094-38.